Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CMPS
stocks logo

CMPS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.390
-38.1%
--
--
-0.310
-25.93%
--
--
-0.330
-19.79%
Estimates Revision
Stock Price
Go Up
up Image
+10.51%
In Past 3 Month
Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.680
sliders
Low
12.00
Averages
21.00
High
40.00
Current: 5.680
sliders
Low
12.00
Averages
21.00
High
40.00
Citizens JMP
Reni Benjamin
Outperform
initiated
$10
2025-12-03
New
Reason
Citizens JMP
Reni Benjamin
Price Target
$10
2025-12-03
New
initiated
Outperform
Reason
Citizens JMP analyst Reni Benjamin initiated coverage of Compass Therapeutics with an Outperform rating and $10 price target. The firm says the company's most-advanced candidate, tovecimig, recently demonstrated a 17% overall response rate in combination with paclitaxel as a treatment for biliary tract cancers versus 5% for the paclitaxel comparison arm in a pivotal Phase 2/3 study. The analyst also believes CTX-10726 "could be a diamond in the rough" for Compass.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$45 -> $40
2025-08-04
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$45 -> $40
2025-08-04
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Compass Pathways to $40 from $45 and keeps a Buy rating on the shares. Compass confirmed that no further development is planned in anorexia nervosa following completion of the Phase 2 trial, the analyst tells investors in a research note. As such, the firm removed the indication from its model post the Q2 report.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
2025-07-15
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
2025-07-15
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating on shares of Compass Pathways, telling investors in a research note that the Phase 3 COMP005 trial delivered a regulatory win for COMP360 and the Phase 3 COMP006 trial is positioned to build on that success. The ongoing COMP006 trial, which is exploring a fixed repeat dosing regimen, is on track for a 26-week data readout in 2H26 and is expected to provide insight into durability and re-dosing strategy with COMP360, the firm says.
Canaccord
Sumant Kulkarni
Buy
maintain
$15
2025-06-24
Reason
Canaccord
Sumant Kulkarni
Price Target
$15
2025-06-24
maintain
Buy
Reason
Canaccord analyst Sumant Kulkarni said the weakness in Compass Pathways following the release of top-line results from its eagerly-awaited COMP005 Phase 3 trial for COMP360 (psilocybin) in treatment-resistant depression (TRD). COMP006, a second Phase 3 trial, is a buying opportunity. Canaccord believes updates from the FDA could eventually move the stock and there is no change tpo their model pending additional data. Canaccord reiterates its Buy rating and $15 price target on Compass Pathways shares.
BTIG
Buy
downgrade
$12 -> $7
2025-06-24
Reason
BTIG
Price Target
$12 -> $7
2025-06-24
downgrade
Buy
Reason
Evercore ISI
Outperform
to
In Line
downgrade
$11 -> $6
2025-06-23
Reason
Evercore ISI
Price Target
$11 -> $6
2025-06-23
downgrade
Outperform
to
In Line
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Compass Pathways PLC (CMPS.O) is -4.27, compared to its 5-year average forward P/E of -7.32. For a more detailed relative valuation and DCF analysis to assess Compass Pathways PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.32
Current PE
-4.27
Overvalued PE
-0.04
Undervalued PE
-14.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.03
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.52
Undervalued EV/EBITDA
-11.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
89.28
Current PS
0.00
Overvalued PS
487.04
Undervalued PS
-308.48
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 302.54% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CMPS News & Events

Events Timeline

(ET)
2025-10-30
08:31:56
Compass Pathways and NeuroKaire Form Research and Development Partnership
select
2025-09-02 (ET)
2025-09-02
06:33:14
Compass Pathways' COMP360 psilocybin demonstrates promising efficacy and tolerance outcomes.
select
2025-07-31 (ET)
2025-07-31
06:36:03
Compass Pathways reports Q2 EPS (41c) vs. (56c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-04SeekingAlpha
COMPASS Pathways Reports ADS GAAP EPS of -$1.44, Falling Short by $1.05

  • Q3 Financial Performance: COMPASS Pathways reported a Q3 GAAP EPS of -$1.44, missing expectations by $1.05, while cash and cash equivalents increased to $185.9 million as of September 30, 2025.

  • Operating Cash Forecast: The company anticipates a full year 2025 net cash usage in operating activities between $120 million to $145 million, with sufficient cash to cover expenses and capital needs into 2027.

[object Object]
Preview
5.0
10-29Newsfilter
Compass Pathways Names Dr. Jeffrey Jonas to Its Board of Directors

  • New Board Appointment: Compass Pathways has appointed Dr. Jeffrey Jonas to its Board of Directors, bringing over 30 years of experience in pharmaceutical research and neuroscience, effective immediately.

  • Retirement Announcement: Thomas Lönngren will retire from the Board at the end of December after more than six years of service, during which he contributed to the company's transition from early-stage to late-stage clinical development.

  • COMP360 Program Focus: The company is advancing its investigational COMP360 synthetic psilocybin treatment for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA.

  • Commitment to Mental Health Innovation: Dr. Jonas expressed enthusiasm for supporting Compass Pathways in transforming mental health care through innovative treatments, emphasizing the urgent need for effective solutions in the growing mental health crisis.

[object Object]
Preview
3.0
10-28Newsfilter
Compass Pathways Set to Release Q3 Financial Results on November 4, 2025

  • Conference Call Announcement: Compass Pathways plc will host a conference call on November 4, 2025, at 8:00 am ET to discuss its third-quarter financial results and recent developments.

  • Webcast Availability: A live webcast of the conference call will be available on the Compass Pathways website and will be archived for 30 days.

  • Company Overview: Compass Pathways is a biotechnology company focused on improving mental health treatment through innovative solutions, including its investigational COMP360 psilocybin treatment.

  • Regulatory Designations: COMP360 has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway designation in the UK for treatment-resistant depression.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Compass Pathways PLC (CMPS) stock price today?

The current price of CMPS is 5.68 USD — it has increased 11.59 % in the last trading day.

arrow icon

What is Compass Pathways PLC (CMPS)'s business?

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

arrow icon

What is the price predicton of CMPS Stock?

Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is 21.00 USD with a low forecast of 12.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Compass Pathways PLC (CMPS)'s revenue for the last quarter?

Compass Pathways PLC revenue for the last quarter amounts to -40.54M USD, decreased -15.37 % YoY.

arrow icon

What is Compass Pathways PLC (CMPS)'s earnings per share (EPS) for the last quarter?

Compass Pathways PLC. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Compass Pathways PLC (CMPS)'s fundamentals?

The market is revising No Change the revenue expectations for CMPS for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 10.51%.
arrow icon

How many employees does Compass Pathways PLC (CMPS). have?

Compass Pathways PLC (CMPS) has 166 emplpoyees as of December 05 2025.

arrow icon

What is Compass Pathways PLC (CMPS) market cap?

Today CMPS has the market capitalization of 545.38M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free